2.27
Aldeyra Therapeutics Inc stock is traded at $2.27, with a volume of 2.12M.
It is down -6.58% in the last 24 hours and up +38.41% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$2.43
Open:
$2.41
24h Volume:
2.12M
Relative Volume:
1.43
Market Cap:
$136.93M
Revenue:
-
Net Income/Loss:
$-27.37M
P/E Ratio:
-4.9868
EPS:
-0.4552
Net Cash Flow:
$-25.99M
1W Performance:
+26.11%
1M Performance:
+38.41%
6M Performance:
-51.39%
1Y Performance:
-43.25%
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics Inc
|
2.27 | 128.48M | 0 | -27.37M | -25.99M | -0.4552 |
|
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Dynamic Index - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 3000E Index - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell Small Cap Completeness Index - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 3000 Index - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Index - marketscreener.com
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
137 Forecast — Price Target — Prediction for 2027 - TradingView
Why Did ALDX Stock Tank 70% Today? - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Price to book forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView
Price to book forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView
ALDX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView
Enterprise value to EBITDA forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView
Enterprise value to revenue forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView
Enterprise value to revenue forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView
Aldeyra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALDX) - TradingView
Aldeyra appoints Darlene Deptula-Hicks to board of directors By Investing.com - Investing.com Nigeria
Aldeyra Therapeutics, Inc. Actuals & Estimates (DUS:137) - TradingView
Price to earnings forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView
Price to sales forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView
Enterprise value to EBIT forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView
Price to earnings forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire
Enterprise value to EBIT forward of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView
Aldeyra Therapeutics, Inc. Actuals & Estimates (MUN:137) - TradingView
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc - The National Law Review
Aldeyra Therapeutics Inc (ALDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Precision Trading with Aldeyra Therapeutics Inc. (ALDX) Risk Zones - Stock Traders Daily
2026-06-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation | NDAQ:ALDX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Aldeyra Therapeutics Inc (ALDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aldeyra Therapeutics Inc (ALDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aldeyra Therapeutics Inc (ALDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aldeyra Therapeutics Inc (ALDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aldeyra Therapeutics Inc (ALDX) Institutional Confidence - TradingKey
Aldeyra Therapeutics Inc (ALDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aldeyra Therapeutics Inc (ALDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
ALDX News | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect - ACCESS Newswire
Aldeyra Therapeutics (ALDX) grants director options on 73,318 shares - Stock Titan
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DOUGLAS RICHARD | Director |
Mar 19 '26 |
Buy |
1.40 |
70,000 |
98,000 |
195,000 |
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
| Alfieri Michael | Principal Financial Officer |
Aug 13 '25 |
Buy |
5.30 |
2,500 |
13,250 |
2,500 |
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):